Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merz Aesthetics Obtains FDA Approval For Asclera Injection
The FDA has approved Asclera (polidocanol) injection on March 30, 2010 to sclerose uncomplicated spider veins (varicose veins less than or equal to 1mm in diameter) and uncomplicated
The FDA has approved Asclera (polidocanol) injection on March 30, 2010 to sclerose uncomplicated spider veins (varicose veins less than or equal to 1mm in diameter) and uncomplicated
Proteo’s drug substance Elafin is a natural human antagonist of elastase and proteinase-3, two potent tissue destroying enzymes, both of which participate in the inflammatory mechanism of a
Health Canada has a 45-day screening for acceptance process of the Rresponse by their Regulatory Project Management group. The acceptance of the Response triggers a new, 150-day review
Bydureon is an investigational, extended-release medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. In accordance with its guidelines,
Sunitinib is currently approved for both gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib mesylate, and advanced / metastatic renal cell carcinoma (RCC) based
Victoza and Januvia are both incretin-based diabetes therapies. Victoza mimics the activity of the naturally-occurring hormone, GLP-1, while Januvia blocks the enzyme responsible for the breakdown of GLP-1
Tryton Medical said that more than 1,000 patients in Europe have been treated with the Tryton Side Branch Stent System, with more than 500 part of a registry
A product development team (PDT) comprised of representatives from Pfizer, MMV and the London School of Hygiene and Tropical Medicine (LSHTM) are expected to coordinate the trials and
AkzoNobel has posted a net income of EUR81m, or EUR0.35 per diluted share, compared to net loss of EUR7m, or EUR0.03 per diluted share, for the prior year
Novartis Pharma claimed that following EC’s decision, the pediatric indication needs to be implemented through EU National Competent Authorities before Diovan will be available for pediatric use across